Partnering to confront a crisis
Opioids represent a large class of medications commonly used to relieve acute and chronic pain, or to help manage opioid abuse and dependence. These medications can produce physical and psychological dependence and have a high risk for abuse and diversion. As a result, many professional practice guidelines recommend compliance testing in patients who are prescribed these medications.
Mayo Clinic Laboratories now offers a targeted, high-resolution mass spectrometry screening assay that does not hydrolyze the urine sample, allowing for both the parent and metabolites of 33 different opioids to be detected. Results of this assay will enable clinicians to accurately detect opioid use and effectively monitor treatment compliance.
Targeted screening for enhanced detection
Ensure adherence to federal and state regulations by:
Substances assessed include, but are not limited to:
Comprehensive monitoring profiles
Profiles which include TOPSU
New high-resolution targeted opioid screen
Paul Jannetto, Ph.D., highlights Mayo Clinic’s new targeted opioid assay, and discusses the advantages and limitations of various urine screening assays and quantitative confirmatory testing to determine compliance to opioid therapy.
Analysis of urine drug testing results by our experts, who apply the most up-to-date scientific data, enables further transparency and clear answers that illuminate patients’ drug use.
Pharmacokinetics of opioids
Substances that can interfere with simple (immunoassay) screening results
Learn more about how to order these tests at your institution.